Department of Community Health Sciences, University of Sherbrooke, Sherbrooke, Canada.
Vaccine. 2009 Nov 23;27(50):7105-9. doi: 10.1016/j.vaccine.2009.09.057. Epub 2009 Sep 26.
In the province of Quebec, Canada, the pneumococcal 7-valent conjugate vaccine (PCV-7) was licensed in 2001 and a publicly funded program was implemented in 2004, recommending 3 doses for healthy children. An economic analysis was performed both from a health care and societal perspective. Outcomes possibly prevented by PCV-7 and observed in 2006-2007 were compared to expected frequencies based on rates measured before PCV-7 use. Annual program costs were close to $21M for the health system and $23M for society. Approximately 20,000 infections were prevented annually and estimated economic benefits were $5M for the health system and $23M for society, using a 3% per annum discounting rate. The incremental cost-effectiveness ratio was $18,000 per QALY gained for the health system and the program was close to the break-even threshold in a societal perspective.
在加拿大魁北克省，肺炎球菌 7 价结合疫苗（PCV-7）于 2001 年获得许可，并于 2004 年实施了一项公共资助计划，建议为健康儿童接种 3 剂。从医疗保健和社会角度进行了经济分析。将 2006-2007 年观察到的 PCV-7 可能预防的结果与 PCV-7 使用前测量的比率预期频率进行了比较。卫生系统的年度计划成本接近 2100 万美元，社会的年度计划成本接近 2300 万美元。使用每年 3%的贴现率，每年可预防约 20,000 例感染，为卫生系统带来约 500 万美元的经济效益，为社会带来约 2300 万美元的经济效益。对于卫生系统，增量成本效益比为每获得一个质量调整生命年增加 18,000 美元，从社会角度来看，该方案接近收支平衡的临界点。
